-
Posted by
Two Blokes Tue at 3:00 AM -
Filed in
Stock
-
2 views
Compass Therapeutics' tovecimig shows promise in biliary tract cancer with a 17.1% response rate, but further survival data is crucial for potential approval. CMPX's cash runway extends into early 2027, providing financial stability to reach key milestones and possibly raise funds from a stronger position. Other pipeline candidates, CTX-471 and CTX-8371, have upcoming trials and readouts in 2025, adding potential value to CMPX's portfolio.
